Stockreport

Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer

Arcus Biosciences, Inc.  (RCUS) 
Last arcus biosciences, inc. earnings: 3/5 04:10 pm Check Earnings Report
PDF Median progression-free survival (mPFS) was 15.1 months, and the confirmed overall response rate (cORR) increased to 45% for the 100mg QD (once daily) tablet cohort in a [Read more]